Resources

This briefing paper underscores the burden of rotavirus and highlights the promise of vaccines to combat the virus as the global health community prepares for worldwide introduction.  

This document outlines PATH's work with private-sector partners to make appropriate household water treatment and storage products accessible and affordable for low-income families.

This compilation contains key references and resources to aid program planners in the introduction of oxytocin in the Uniject™ prefilled injection device.

Produced by project Optimize and the vaccine technologies team at PATH, this report: (1) summarizes the clinical evidence supporting the intradermal route for vaccine administration and the devices being developed for this purpose; (2) determines whether intradermal delivery broadly holds promise for vaccine applications for low- and middle-income countries in the future; and (3) begins to prioritize vaccine targets and device strategies that best fit the public health needs in these countries and likely merit further investigation. The document is available as one large file or as four smaller files for easier downloading.

This article, published in Human Vaccines (Human Vaccines 5:8, 1-7; August 2009), details a collaborative effort between PATH, Arecor, and the University of Colorado Denver School of Pharmacy that has resulted in a new formulation for recombinant hepatitis B vaccine that demonstrates improved stability at elevated temperatures. The formulation exhibited 9-week stability at 55°C and was also shown to be stable at both 37°C and 45°C for at least six months. This new vaccine formulation has the potential to be stored at room temperature for part of its shelf life and will help ensure the potency of the vaccine in areas where the cold chain is insufficient.